J2N-OX-JZNN - ClinicalTrials.gov - NCT04666038
J2N-OX-JZNN - ClinicalTrials.gov - NCT04666038
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Have chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment
Have received prior treatment, including with a type of medicine called a BTK inhibitor
Be well enough to perform their own personal care
Have adequate organ function and blood counts, as measured by blood tests
Participants must NOT
Have cancer that has become very aggressive or has spread to the brain or spinal cord
Have serious heart disease
Need a blood thinner called warfarin
Have any problems absorbing food or medicine taken by mouth
Take certain medicines that affect how fast the study drug is broken down in the body
Have active infection
Trial Summary
Conditions the trial is for
Leukemia, Lymphoma
What the trial is testing?
Pirtobrutinib (LOXO-305), Idelalisib plus Rituximab (IdelaR), Bendamustine plus Rituximab (BR)
Could I receive a Placebo?
no
Enrollment Goal
250
Trial Dates
March 2021 - July 2023
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Have chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment
Have received prior treatment, including with a type of medicine called a BTK inhibitor
Be well enough to perform their own personal care
Have adequate organ function and blood counts, as measured by blood tests
Participants must NOT
Have cancer that has become very aggressive or has spread to the brain or spinal cord
Have serious heart disease
Need a blood thinner called warfarin
Have any problems absorbing food or medicine taken by mouth
Take certain medicines that affect how fast the study drug is broken down in the body
Have active infection
Trial Summary
Conditions the trial is for
Leukemia, Lymphoma
What the trial is testing?
Pirtobrutinib (LOXO-305), Idelalisib plus Rituximab (IdelaR), Bendamustine plus Rituximab (BR)
Could I receive a Placebo?
no
Enrollment Goal
250
Trial Dates
March 2021 - July 2023
Trial Phase
3
Trial Locations
Hide locations not currently recruiting